Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection

被引：3

作者：

Signorovitch, James E. ^{[1
]}

Betts, Keith A. ^{[1
]}

Song, Yan ^{[1
]}

Sorg, Rachael A. ^{[2
]}

Li, Junlong ^{[1
]}

Behl, Ajay S. ^{[3
]}

Kalsekar, Anupama ^{[3
]}

机构：

[1] Anal Grp Inc, Boston, MA 02199 USA

[2] Anal Grp Inc, New York, NY USA

[3] Bristol Myers Squibb Co, Princeton, NJ USA

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2015年 / 4卷 / 06期

关键词：

asunaprevir; daclatasvir; direct-acting antiviral agents; genotype; 1b; hepatitis C; TREATMENT-NAIVE PATIENTS; DACLATASVIR PLUS ASUNAPREVIR; PEGYLATED INTERFERON ALPHA-2A; ADJUSTED INDIRECT COMPARISONS; ISPOR TASK-FORCE; PEGINTERFERON ALPHA-2A; NETWORK METAANALYSIS; 1-INFECTED PATIENTS; DOUBLE-BLIND; HCV;

D O I：

10.2217/cer.15.33

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aim: Efficacy and safety comparison of daclatasvir/asunaprevir (DCV + ASV) versus peginterferon-/ribavirin (A/R) alone or combined with telaprevir, boceprevir, simeprevir or sofosbuvir in chronic genotype 1b hepatitis C virus infection. Methods: Network meta-analysis (NMA) and matching-adjusted indirect comparisons (MAICs). Results: Among treatment-naive patients, DCV + ASV demonstrated higher sustained virologic response (SVR) rates than telaprevir + A/R, boceprevir + A/R and A/R in NMA and MAICs and simeprevir + A/R in NMA. DCV + ASV among treatment-experienced patients had higher SVR rates than telaprevir + A/R, boceprevir + A/R, simeprevir + A/R and A/R in MAICs. DCV + ASV had lower adverse events rates than comparators. Conclusion: DCV + ASV demonstrated superior efficacy and safety compared with A/R-based regimens

引用

页码：593 / 605

页数：13

共 56 条

[1] Extending methods for investigating the relationship between treatment effect and baseline risk from pairwise meta-analysis to network meta-analysis [J].

Achana, Felix A. ;

Cooper, Nicola J. ;

Dias, Sofia ;

Lu, Guobing ;

Rice, Stephen J. C. ;

Kendrick, Denise ;

Sutton, Alex J. .

STATISTICS IN MEDICINE, 2013, 32 (05) :752-771

[2] Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection [J].

Afdhal, Nezam ;

Reddy, K. Rajender ;

Nelson, David R. ;

Lawitz, Eric ;

Gordon, Stuart C. ;

Schiff, Eugene ;

Nahass, Ronald ;

Ghalib, Reem ;

Gitlin, Norman ;

Herring, Robert ;

Lalezari, Jacob ;

Younes, Ziad H. ;

Pockros, Paul J. ;

Di Bisceglie, Adrian M. ;

Arora, Sanjeev ;

Subramanian, G. Mani ;

Zhu, Yanni ;

Dvory-Sobol, Hadas ;

Yang, Jenny C. ;

Pang, Phillip S. ;

Symonds, William T. ;

McHutchison, John G. ;

Muir, Andrew J. ;

Sulkowski, Mark ;

Kwo, Paul .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (16) :1483-1493

[3]

American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, 2014, REC TEST MAN HEP C

[4] Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection [J].

Bacon, Bruce R. ;

Gordon, Stuart C. ;

Lawitz, Eric ;

Marcellin, Patrick ;

Vierling, John M. ;

Zeuzem, Stefan ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Boparai, Navdeep ;

Burroughs, Margaret ;

Brass, Clifford A. ;

Albrecht, Janice K. ;

Esteban, Rafael .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1207-1217

[5] The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials [J].

Bucher, HC ;

Guyatt, GH ;

Griffith, LE ;

Walter, SD .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 1997, 50 (06) :683-691

[6] Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C [J].

Buti, Maria ;

Agarwal, Kosh ;

Horsmans, Yves ;

Sievert, William ;

Janczewska, Ewa ;

Zeuzem, Stefan ;

Nyberg, Lisa ;

Brown, Robert S., Jr. ;

Hezode, Christophe ;

Rizzetto, Mario ;

Parana, Raymundo ;

De Meyer, Sandra ;

De Masi, Ralph ;

Luo, Donghan ;

Bertelsen, Kirk ;

Witek, James .

GASTROENTEROLOGY, 2014, 146 (03) :744-+

[7] Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis [J].

Camma, Calogero ;

Cabibbo, Giuseppe ;

Bronte, Fabrizio ;

Enea, Marco ;

Licata, Anna ;

Attanasio, Massimo ;

Andriulli, Angelo ;

Craxi, Antonio .

JOURNAL OF HEPATOLOGY, 2009, 51 (04) :675-681

[8] Efficacy of pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis [J].

Coppola, Nicola ;

Pisaturo, Mariantonietta ;

Tonziello, Gilda ;

Sagnelli, Caterina ;

Sagnelli, Evangelista ;

Angelillo, Italo F. .

BMC INFECTIOUS DISEASES, 2012, 12

[9] A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel [J].

Cornberg, Markus ;

Razavi, Homie A. ;

Alberti, Alfredo ;

Bernasconi, Enos ;

Buti, Maria ;

Cooper, Curtis ;

Dalgard, Olav ;

Dillion, John F. ;

Flisiak, Robert ;

Forns, Xavier ;

Frankova, Sona ;

Goldis, Adrian ;

Goulis, Ioannis ;

Halota, Waldemar ;

Hunyady, Bela ;

Lagging, Martin ;

Largen, Angela ;

Makara, Michael ;

Manolakopoulos, Spilios ;

Marcellin, Patrick ;

Marinho, Rui T. ;

Pol, Stanislas ;

Poynard, Thierry ;

Puoti, Massimo ;

Sagalova, Olga ;

Sibbel, Scott ;

Simon, Krzysztof ;

Wallace, Carolyn ;

Young, Kendra ;

Yurdaydin, Cihan ;

Zuckerman, Eli ;

Negro, Francesco ;

Zeuzem, Stefan .

LIVER INTERNATIONAL, 2011, 31 :30-60

[10] Characterization of Telaprevir Treatment Outcomes and Resistance in Patients With Prior Treatment Failure: Results From the REALIZE Trial [J].

De Meyer, Sandra ;

Dierynck, Inge ;

Ghys, Anne ;

Beumont, Maria ;

Daems, Bjorn ;

Van Baelen, Ben ;

Sullivan, James C. ;

Bartels, Douglas J. ;

Kieffer, Tara L. ;

Zeuzem, Stefan ;

Picchio, Gaston .

HEPATOLOGY, 2012, 56 (06) :2106-2115

← 1 2 3 4 5 6 →